NCT07008872View on ClinicalTrials.gov

CD7 CAR-T Cell Therapy Targeting CD7-positive Relapsed/Refractory T Cell Lymphoma/Acute Leukemia

NANot yet recruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

June 1, 2025

Primary Completion Date

May 31, 2027

Study Completion Date

May 31, 2027

Conditions
CD7+ LymphomaCD7+ Acute Leukemia
Interventions
BIOLOGICAL

CD7 CART

For intravenous infusion

All Listed Sponsors
collaborator

Hebei Taihe Chunyu Biotechnology Co., Ltd

INDUSTRY

lead

Qi deng

OTHER

NCT07008872 - CD7 CAR-T Cell Therapy Targeting CD7-positive Relapsed/Refractory T Cell Lymphoma/Acute Leukemia | Biotech Hunter | Biotech Hunter